Tagged with GSK,

France Josephine Yang Comiskey, president of GSK France, gives insights into GSK’s corporate culture, portfolio and priorities in France. She also highlights the need for collaboration and a better dialogue between industry and authorities, to ensure quicker market access for innovative products in the country.   We welcome the fact that…

Korea Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for GSK – vaccines, HIV and respiratory treatments, and provides an insight into how GSK can best utilize Korea’s strong environment…

UK The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products with a market share of 7.3 percent.   This move will see GSK effectively split into two separate businesses –…

Cyprus Mario Sciberras, former general manager for Malta and Gibraltar became general manager for Cyprus, Malta, and Gibraltar in 2016. In this interview, he touches on themes of transparency, GSK’s positioning on the market and its vaccination strategy for the coming years. What have been your main priorities since taking over…

GSK KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide…

Brexit Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms ever closer, industry professionals fervently speculate on how it will affect the country’s position as one of the world’s great…

Turkey Selim Giray, the recently appointed VP and general manager of GSK Turkey, provides insights into the company’s eye-catching footprint and commitment to Turkey, his ambition to integrate into the market’s Top Four ranking in the coming years, as well as his aspirations to see the industry and the government work…

Pharma What is VR and why should healthcare and pharmaceutical companies take note? VR (Virtual Reality) places the user into a virtual world. VR differs from Augmented Reality (AR), which sets virtual objects against the backdrop of the real world—as in Pokemon Go, the augmented reality smartphone craze of 2016—or simply…

GSK In a pharmaceutical environment faced with stiffening regulatory regimes, and where mergers and acquisitions become more commonplace, GSK’s diversifications and growth model have long come into question. Historically, Big Pharma would work as a one-stop-shop for medicine solutions covering all therapeutic areas, and over the years, companies opened up new…

Portugal Hailing from the Dominican Republic, Silvia Guichardo brings a fresh perspective as well as both US and Iberian experience to GSK Portugal. Six months into her role as general manager, Guichardo highlights GSK’s historic commitment to Portuguese patients, new therapeutic areas for 2019, and the unsung importance of leading a…

India A successful commercial leader, Annaswamy Vaidheesh, president of OPPI, VP South Asia and managing director at GSK India, talks about the tremendous work that the local affiliate is doing in the country in making innovative products available to patients and their recent GBP 100 million investment in manufacturing. Can you…

Serbia Marija Krstic, general manager of GSK Serbia and Montenegro, discusses how the various positions she has undertaken during her 13-year career at GSK help inform her current role, the initiatives that GSK Serbia is involved in to increase access to innovative medicines for Serbian patients, and her push to ensure…